Targeting this overactivated MAPK pathway with inhibitors is one of the new strategies to treat aCML patients with mutated N/KRAS that is currently under investigation in clinical trials. Here, KRAS is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.